HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM)

CUSIP: 40434H104

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class
Equity / COM
Total 13F shares
2,983,120
Share change
+96,907
Total reported value
$20,643,220
Price per share
$6.92
Number of holders
20
Value change
+$673,643
Number of buys
10
Number of sells
3

Quarterly Holders Quick Answers

What is CUSIP 40434H104?
CUSIP 40434H104 identifies HTGM - HTG MOLECULAR DIAGNOSTICS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) as of Q1 2017

As of 31 Mar 2017, HTG MOLECULAR DIAGNOSTICS IN - COM (HTGM) was held by 20 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 2,983,120 shares. The largest 10 holders included Novo A/S, FMR LLC, PUTNAM INVESTMENTS LLC, Cormorant Asset Management, LLC, VANGUARD GROUP INC, STATE STREET CORP, GRANAHAN INVESTMENT MANAGEMENT INC/MA, TWO SIGMA SECURITIES, LLC, GEODE CAPITAL MANAGEMENT, LLC, and UBS Group AG. This page lists 20 institutional shareholders reporting positions in this security for the Q1 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.